BRITISH JOURNAL OF HAEMATOLOGY英国血液学杂志
BRITISH JOURNAL OF HAEMATOLOGY(英文缩写 BRIT J HAEMATOL),ISSN 0007-1048,eISSN 1365-2141,中文译名:英国血液学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 8.615 | Q1 |
| 2022 | 6.500 | Q1 |
| 2023 | 5.100 | Q1 |
| 2024 | 3.800 | Q1 |
| 2025 | 3.600 | Q2 |
BRITISH JOURNAL OF HAEMATOLOGY 最新收录文献
-
1. KMT2A amplification marks TP53-altered, complex-karyotype malignant clones in haematological malignancies.
PMID:日期:2026-10-05该文献暂无摘要。
-
4. Racial disparities in anaemia associated with paediatric chronic kidney disease.
PMID:日期:2026-09-24该文献暂无摘要。
-
5. Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests.
PMID:日期:2026-09-24Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work-up in primary care. We aimed to develop a tool for estimating overall risk of haematological malignancy in primary care patients using simple data inputs. Including all full blood cell counts (FBCs) measured from 2000 to 2016 in 856 403 adult primary care patients in Eastern Denmark, we used machine learning to develop CBC-HEMA, a risk assessment tool using FBCs, age, sex and C-reactive protein measures to stratify 'any haematological malignancy' risk within 6 months, 1 year and 3 years with area under the curve (AUC) of 0.81, 0.78 and 0.71 respectively. Predictions of chronic lymphoid leukaemia and myeloproliferative disease were excellent, while CBC-HEMA was unable to accurately predict non-Hodgkin lymphoma and plasma cell dyscrasia. External validation was conducted in 123 015 primary care patients from Western Denmark with similar results and in 418 410 individuals from the background population cohort UK Biobank with inferior performance showing unfitness in screening healthy populations. The CBC-HEMA https://shiny.sund.ku.dk/CopLab/blood-cancer-risk-prediction/ may support risk assessment in primary care but cannot replace a clinical evaluation.
-
6. SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models.
PMID:日期:2026-09-24Acute myeloid leukaemia (AML) is supported by leukaemic stem cells (LSCs), whose continued existence and growth are dependent upon signals derived from their bone marrow (BM) microenvironment. Although the highly conserved glycoprotein slit guidance ligand 2 (SLIT2), implicated in axon guidance, has been proposed to support normal haematopoietic stem cell (HSC) function, its role in AML pathogenesis remains poorly defined. Here, we show that SLIT2 is downregulated in mesenchymal stem cells (MSCs) from AML patients. Patients with higher-than-normal SLIT2 protein levels had better outcomes, independently of classical risk factors. Functionally, knocking down (KD) SLIT2 in MSCs caused a reprogramming of the microenvironment. Specifically, SLIT2-KD in MSCs resulted in increased expression of LSC-supporting genes including C-X-C motif chemokne ligand 12 (CXCL12) and KIT proto-oncogene, receptor tyrosine kinase (KIT), and co-culture of primary AML cells on SLIT2-KD stromal cells prevented myeloid differentiation. Conversely, the addition of recombinant SLIT2 had cytostatic effects on AML cells, resulting in reduced proliferation and reduced clonogenicity in all tested models. Furthermore, in human xenograft models, systemic administration of recombinant SLIT2 resulted in a decrease in leukaemic burden in BM and spleen, delayed disease progression and improved survival. Overall, these data demonstrate that SLIT2 may act as a tumour suppressor, while SLIT2 loss impairs myeloid terminal differentiation, suggesting that SLIT2 signalling could serve as a potential therapeutic axis in AML.
-
7. Disease-directed progress in myeloproliferative neoplasms also needs closed-loop distress and care coordination.
7. 骨髓增殖性肿瘤的疾病导向进展也需要闭环式的痛苦管理与照护协调PMID:日期:2026-09-24该文献暂无摘要。
-
10. Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.
PMID:日期:2026-09-22SeaLAND (ALLG MM23, ACTRN12620000291987) was a randomized, open-label phase III study evaluating low-dose weekly selinexor (40 mg) plus lenalidomide (selinexor-R) versus lenalidomide alone (R) as post-transplant maintenance therapy for newly diagnosed, transplant-eligible multiple myeloma. A total of 142 patients were enrolled (R = 64; selinexor-R = 78); the trial closed early for futility. At best response, the complete response (≥CR) rate was numerically, but not significantly, higher with selinexor-R than R (67% vs. 53%, p = 0.09). At 24 months median follow-up, progression-free survival (PFS) was not significantly different between selinexor-R compared to R (hazard ratio [HR] = 1.22; 95% confidence interval [CI] 0.62-2.41; p = 0.56); 24-month PFS rates were 73% (95% CI 57%-84%) for R and 70% (95% CI: 56%-81%) for selinexor-R. The mean relative dose intensity (RDI) of R was lower in the selinexor-R arm compared to R alone (68% vs. 81%, p = 0.002); the mean RDI of S was 55%. Grade ≥3 adverse events were more frequent with selinexor-R (85% vs. 45%, p < 0.001). Common severe non-haematological adverse events included infections (R: 6%, selinexor-R: 19%, p < 0.01) and gastrointestinal disorders (R: 3%, selinexor-R: 14%, p < 0.05). Selinexor-R maintenance did not improve PFS and substantially increased toxicity. Selinexor-R maintenance cannot be recommended for the general myeloma population; we did not observe a benefit among high-risk disease.